The Center for Biosimilars® recaps the top stories for the week of January 27, 2020.
Hi, I’m Matthew Gavidia for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of January 27, 2020.
Number 5: Health New England, a nonprofit health plan in Massachusetts, says it achieved 93% utilization of biosimilar infliximab by requiring prior authorization of the brand product, Remicade.
Number 4: An industry executive with Boehringer Ingelheim discusses the impact that the international pricing index could have on drug development.
Number 3: Developing trust in a biosimilar and working out a long-range, multipronged marketing strategy is key to a successful launch, industry executives say.
Number 2: Panelists at the Specialty Therapies and Biosimilars Conference review how successive patents can be filed to keep an original product in a position of market dominance.
Number 1: Pfizer says its 3 oncology biosimilar products—bevacizumab, rituximab, and trastuzumab—will have the lowest wholesale acquisition cost among all other oncology biosimilars.
To read all of these articles and more, visit centerforbiosimilars.com.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf
October 25th 2024At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence in ensuring the resilience of biosimilar and generic drug production.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.